ReviewRegenerative biomaterials2026
Harnessing extracellular vesicles for ischemic stroke management.
Review in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosomes in inflammatory tissue injury: key pathogenic factors and promising therapeutic agents.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EVs) are versatile, cell-derived complexes that serve as a complete package of biologically important molecules, released during both normal and pathological processes. With rapid advancements in EVs research, there has been a shift in its therapeutic applications, clinical development and commercialization. EVs have been extensively studied for their potential to mitigate ischemic stroke pathological mechanisms, such as excitotoxicity, immune response, blood-brain barrier (BBB) dysfunction, neuroinflammation and apoptosis. EVs' innate ability to protect molecular cargo (proteins, DNA or RNA) from enzymatic degradation, their natural ability to traverse BBB, high cargo-loading efficiency and superior biocompatibility make them ideal candidates for targeted drug delivery systems in ischemic stroke. Their presence in most biofluids and changes in their contents during disease conditions, support investigation of EVs as promising minimally invasive biomarkers for the early diagnosis and treatment monitoring of ischemic stroke. Moreover, EVs in combination with other therapeutic agents have considerable potential for clinical translation. This perspective provides a comprehensive overview of current literature on EV-based systems in stroke management, highlighting their role as standalone therapeutics, presenting opportunities for cargo delivery, biomarkers discovery and synergistic component of combination therapies. Additionally, the ongoing clinical trials are discussed along with the challenges and considerations required to advance the clinical translation and adaptation of EV-based systems for ischemic stroke management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.